Skip to main content
. 2019 Nov 29;9:1295. doi: 10.3389/fonc.2019.01295

Table 4.

Performance of circulating biomarkers in comparison with KRAS mutation in tissue for malignancy prediction.

Tests Patient number (n) Sensitivity (%) Specificity (%)
KRAS MAF in
PB or PC tissue
43 42 100
KRAS MAF in ctDNA 93 47 80
CA19-9 100 76 85
Combination assay of
ctDNA and CA19-9
93 82 81

MAF, mutant allele fraction; ctDNA, circulating tumor DNA.